Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Invested Capital: 2010-2025

Historic Invested Capital for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to -$64.7 million.

  • Ironwood Pharmaceuticals' Invested Capital rose 79.23% to -$64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.7 million, marking a year-over-year increase of 79.23%. This contributed to the annual value of -$301.3 million for FY2024, which is 105.36% down from last year.
  • Ironwood Pharmaceuticals' Invested Capital amounted to -$64.7 million in Q3 2025, which was up 40.59% from -$108.8 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Invested Capital peaked at $722.8 million during Q4 2021, and registered a low of -$334.1 million during Q1 2025.
  • For the 3-year period, Ironwood Pharmaceuticals' Invested Capital averaged around -$117.0 million, with its median value being -$146.7 million (2023).
  • In the last 5 years, Ironwood Pharmaceuticals' Invested Capital surged by 11,667.84% in 2021 and then tumbled by 155.55% in 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Invested Capital (Quarterly) stood at $722.8 million in 2021, then declined by 9.74% to $652.4 million in 2022, then plummeted by 122.49% to -$146.7 million in 2023, then tumbled by 105.36% to -$301.3 million in 2024, then surged by 79.23% to -$64.7 million in 2025.
  • Its Invested Capital was -$64.7 million in Q3 2025, compared to -$108.8 million in Q2 2025 and -$334.1 million in Q1 2025.